Top

Published in:

01-07-2007

Detection and Management of Extrahepatic Colorectal Cancer in Patients with Resectable Liver Metastases

Authors: Yolanda Y. L. Yang, James W. Fleshman, Steven M. Strasberg

Published in: Journal of Gastrointestinal Surgery | Issue 7/2007

Abstract

The presence of extrahepatic disease has a great effect on the management of patients with metastatic colorectal cancer in the liver. FDG-PET scanning is currently the most sensitive way of detecting extrahepatic metastases in such patients. This is supported by 10 studies, which show that FDG-PET scan will discover extrahepatic disease in about one in six patients who have completed standard imaging. Staging laparoscopy is another means of detecting extrahepatic disease. Its role remains undefined especially in patients who have had FDG-PET scans. It should probably be restricted to patients with high clinical risk scores. In terms of treatment, patients with recurrence at the primary colorectal site as well as resectable liver metastases appear to benefit from resection of both sites provided that R0 resections can be obtained. Resection of involved hepatic pedicle lymph nodes in patients with resectable liver metastases is associated with poor outcome. The situation regarding patients with peritoneal and liver metastases bears a strong resemblance to that of primary site recurrence and liver metastases. Very acceptable survival can be expected if the peritoneal disease can be eradicated. Information regarding treatment of lung and liver metastases is the most complete of any of these areas. Good results may be expected if all the disease can be cleared. Caution is required in interpreting claims of good survival when study numbers are small and confidence intervals of data are not provided.

Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002;224:748–756.

Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 1177;41:1177–1189.

Bipat S, van Leeuwen MS, Comans EFI, Pijl MEJ, Bossuyt PMM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. Radiology 2005;237:123–131.PubMedCrossRef

Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999;178:282–287.PubMedCrossRef

Lai DT, Fulham M, Stephen MS, Chu KM, Solomon M, Thompson JF, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131:703–707.PubMed

Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan, D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study [see comment]. Ann Surg 2001;233:293–299.PubMedCrossRef

Schussler-Fiorenza CM, Mahvi DM, Niederhuber J, Rikkers LF, Weber SM. Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastroint Surg 2004;8:150–157.CrossRef

Rosa F, Meimarakis G, Stahl A, Bumm R, Hahn K, Tatsch K, et al. Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease. Nuclear Medizin 2004;43:135–140.

Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002;20:388–395.PubMedCrossRef

10.

Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 2000;21:793–798.PubMedCrossRef

11.

Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21–26.PubMedCrossRef

12.

Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Europ J Surg Oncol 2004;30(3):286–291.CrossRef

13.

Truant S, Huglo D, Hebbar M, Ernst O, Steinling M, & Pruvot, FR. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Brit J Surg 2005;92:362–369.PubMedCrossRef

14.

Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027–1034.PubMedCrossRef

15.

Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin North America 2003;12:165–192.

16.

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999;230:309–318; discussion 318–321.PubMedCrossRef

17.

Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, et al. Hepatic resection for metastatic colorectal adenocarcinoma: A proposal of a prognostic scoring system. J Am Coll of Surg 1999;189:291–299.CrossRef

18.

Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. European J Nuc Med Mol Imag 2002;29:915–921.CrossRef

19.

Libutti SK, Alexander HR Jr, Choyke P, Bartlett DL, Bacharach SL, Whatley M, et al. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 2001;8:779–786.PubMedCrossRef

20.

Zervos EE, Badgwell BD, Burak WE Jr, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 2001;130:636–643; discussion 643–644.PubMedCrossRef

21.

Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: The utility of positron emission tomography (PET). European Journal of Cancer 2001;37:862–869.PubMedCrossRef

22.

Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319–323.PubMedCrossRef

23.

Liu FY, Chen JS, Changchien CR, Yeh CY, Liu SH, Ho KC, et al. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Col & Rect 2005;48:1900–1912.CrossRef

24.

Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Canc Res 2005;11:2785–2808.CrossRef

25.

Rahusen FD, Cuesta MA, Borgstein PJ, Bleichrodt RP, Barkhof F, Doesburg T, et al. Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography [see comment]. Ann Surg 1999;230:31–37.PubMedCrossRef

26.

Jarnagin WR, Conlon K, Bodniewicz J, Dougherty E, DeMatteo RP, Blumgart LH, et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 2001;91(6):1121–1128.PubMedCrossRef

27.

de Castro SM, Tilleman EH, Busch OR, van Delden OM, Lameris JS, van Gulik TM, et al. Diagnostic laparoscopy for primary and secondary liver malignancies: Impact of improved imaging and changed criteria for resection. Ann Surg Oncol 2004;11:522–529.PubMedCrossRef

28.

Grobmyer SR, Fong Y, D’Angelica M, Dematteo RP, Blumgart LH, Jarnagin WR. Diagnostic laparoscopy prior to planned hepatic resection for colorectal metastases. Arch Surg 2004;139:1326–1330.PubMedCrossRef

29.

Koea J, Rodgers M, Thompson P, Woodfield J, Holden A, McCall J. Laparoscopy in the management of colorectal cancer metastatic to the liver. ANZ J Surg 2004;74:1056–1059.PubMedCrossRef

30.

Thaler K, Kanneganti S, Khajanchee Y, Wilson C, Swanstrom L, Hansen PD. The evolving role of staging laparoscopy in the treatment of colorectal hepatic metastasis. Arch Surg 2005;140:727–734.PubMedCrossRef

31.

Luque-de Leon E, Tsiotos GG, Balsiger B, Barnwell J, Burgart LJ, Sarr MG. Staging laparoscopy for pancreatic cancer should be used to select the best means of palliation and not only to maximize the resectability rate. J Gastrointest Surg 1999;3:111–117.PubMedCrossRef

32.

Rydzewski B, Dehdashti F, Gordon BA, Teefey SA, Strasberg SM, Siegel BA. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. Am J Roentgenol 2002;178:353–358.

33.

Bollschweiler E. Benefits and limitations of Kaplan–Meier calculations of survival chance in cancer surgery. Langenbeck’s Arch Surg 2003;388:239–244.CrossRef

34.

Hahnloser D, Nelson H, Gunderson LL, Hassan I, Haddock MG, O’Connell MJ, et al. Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg 2003;237:502–508.PubMedCrossRef

35.

Vermaas M, Ferenschild FT, Nuyttens JJ, Marinelli AW, Wiggers T, van der Sijp JR, et al. Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Col & Rect 2005;48:918–928.CrossRef

36.

Bakx R, van Tinteren H, van Lanschot JJ, Zoetmulder FA. Surgical treatment of locally recurrent rectal cancer. Europ J Surg Oncol 2004;30:857–863.

37.

Shoup M, Guillem JG, Alektiar KM, Liau K, Paty PB, Cohen AM, et al. Predictors of survival in recurrent rectal cancer after resection and intraoperative radiotherapy. Dis Col & Rect 2002;45:585–592.CrossRef

38.

Yamada K, Ishizawa T, Niwa K, Chuman Y, Akiba S, Aikou T. Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer. Brit J Surg 2001;8:988–993.CrossRef

39.

Hartley JE, Lopez RA, Paty PB, Wong WD, Cohen AM, Guillem JG. Resection of locally recurrent colorectal cancer in the presence of distant metastases: Can it be justified? Ann Surg Oncol 2003;10:227–233.PubMedCrossRef

40.

Bowne WB, Lee B, Wong WD, Ben-Porat L, Shia J, Cohen AM, et al. Operative salvage for locoregional recurrent colon cancer after curative resection: An analysis of 100 cases. Dis Col & Rect 2005;48:897–909.CrossRef

41.

August DA, Sugarbaker PH, Schneider PD. Lymphatic dissemination of hepatic metastases. Implications for the follow-up and treatment of patients with colorectal cancer. Cancer 1985;55:1490–1494.PubMedCrossRef

42.

Jaeck D, Nakano H, Bachellier P, Inoue K, Weber JC, Oussoultzoglou E, et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: A prospective study. [see comment]. Ann Surg Oncol 2002;9:430–438.PubMedCrossRef

43.

Kokudo N, Sato T, Seki M, Ohta H, Azekura K, Ueno M, et al. Hepatic lymph node involvement in resected cases of liver metastases from colorectal cancer. Dis Col & Rect 1999;42(10):1285–1290; discussion 1290–1291.CrossRef

44.

Elias D, Saric J, Jaeck D, Arnaud JP, Gayet B, Rivoire M, et al. Prospective study of microscopic lymph node involvement of the hepatic pedicle during curative hepatectomy for colorectal metastases. Brit J Surg 1996;83:942–945.PubMedCrossRef

45.

Couinaud C. Lymphatic drainage of the liver. In Couinaud C, ed. Controlled hepatectomies and exposure of the intrahepatic bile ducts. Anatomical and technical study. Paris, France: C. Couinaud, 1981.

46.

Tsuji T, Hiraoka T, Kanemitsu K, Takamori H, Tanabe D, Tashiro S. Lymphatic spreading pattern of intrahepatic cholangiocarcinoma. Surgery 2001;129(4):401–407.PubMed

47.

Elias DM, Ouellet JF. Incidence, distribution, and significance of hilar lymph node metastases in hepatic colorectal metastases. Surg Oncol Clin North America 2003;12:221–229.CrossRef

48.

Laurent C, Sa Cunha A, Rullier E, Smith D, Rullier A, Saric J. Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg 2004;198:884–891.PubMedCrossRef

49.

Beckurts KT, Holscher AH, Thorban S, Bollschweiler E, Siewert, JR. Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Brit J Surg 1997;84:1081–1084.PubMedCrossRef

50.

Nakamura S, Suzuki S, Konno H. Resection of hepatic metastases of colorectal carcinoma: 20 years’ experience. J HPB Surg 1999;6:16–22.

51.

Rodgers MS, McCall, JL. Surgery for colorectal liver metastases with hepatic lymph node involvement: A systematic review [see comment] [erratum appears in Br J Surg 2001 Mar;88(3):472]. Brit J Surg 2000;87:1142–1155.PubMedCrossRef

52.

Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver. Optimizing the results of treatment. Surg Clin North America 1989;69:339–359.

53.

Nordlinger B, Jaeck D, Guiguet M, Vaillant J, Balladur PJCS. Resection chiurgicale des metastates hepatique. Enquete de l’Association Francaise de Chirurgie. In: Monographies de l’Association Francaise de Chirurgie. Traitement Des Metastases Hepatiques Des Cancer Colorectaux. Paris: Springer, 1992 pp 129–146.

54.

Sugarbaker PH. A curative approach to peritoneal carcinomatosis from colorectal cancer. Sem Oncol 2005;32(6 Suppl 9):S68–S73.CrossRef

55.

Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer [see comment]. J Clin Oncol 2003;21:3737–3743.PubMedCrossRef

56.

Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005;12:65–71.PubMedCrossRef

57.

Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22:3284–3292.PubMedCrossRef

58.

Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Brit J Surg 1990;77:1241–1246.PubMedCrossRef

59.

McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases. 10-year results. Arch Surg 1992;127:1403–1406.PubMed

60.

Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North America 2002;82:1075–1090.CrossRef

61.

Headrick JR, Miller DL, Nagorney DM, Allen MS, Deschamps C, Trastek VF, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975–979.PubMedCrossRef

62.

Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006;202:468–475.PubMedCrossRef

63.

Regnard J-F, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998;66:214–218.PubMedCrossRef

64.

Ike H, Shimada H, Togo S, Yamaguchi S, Ichikawa Y, Tanaka K. Sequential resection of lung metastasis following partial hepatectomy for colorectal cancer. British Journal of Surgery 2002;89(9):1164–1168.PubMedCrossRef

65.

Murata S, Moriya Y, Akasu T, Fujita S, Sugihara, K. Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998;83:1086–1093.PubMedCrossRef

66.

Kobayashi K, Kawamura M, Ishihara T. Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. Journal of Thoracic & Cardiovascular Surgery 1999;118(6);1090–1096.CrossRef

67.

Robinson BJ, Rice TW, Strong SA, Rybicki LA, Blackstone, EH. Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? Journal of Thoracic and Cardiovascular Surgery 1999;117:66–75.PubMedCrossRef

68.

Nagakura S, Shirai Y, Yamato Y, Yokoyama N, Suda T, Hatakeyama K. Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 2001;193:153–160.PubMedCrossRef

69.

Mineo TC, Ambrogi V, Tonini G, Bollero P, Roselli M, Mineo D, et al. Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg 2003;197:386–391.PubMedCrossRef

70.

Reddy RHV, Kumar B, Shah R, Mirsadraee S, Papagiannopoulos K, Lodge P, et al. Staged pulmonary and hepatic metastasectomy in colorectal cancer-is it worth it? Europ J Cardio-Thorac Surg 2004;25:151–154.CrossRef

71.

Patel NA, Keenan RJ, Medich DS, Woo Y, Celebrezze J, Santucci T, et al. The presence of colorectal hepatic metastases does not preclude pulmonary metastasectomy. Am Surg 2003;69:1047–1053.PubMed

72.

Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Kato A, et al. Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998;82:274–278.PubMedCrossRef

73.

Lehnert T, Knaebel HP, Dück M, Bülzebruck H, Herfarth C. Sequential hepatic and pulmonary resections for metastatic colorectal cancer. Brit J Surg 1999;86:241–243.PubMedCrossRef

74.

Labow DM, Buell JF, Yoshida A, Rosen S, Posner MC. Isolated pulmonary recurrence after resection of colorectal hepatic metastases—is resection indicated? The Cancer Journal 2002;8:342–347.PubMed

75.

Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, et al. Hepatic and extrahepatic colorectal metastases: When resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900–909.PubMedCrossRef

76.

Strasberg SM. Letter to editor. Ann Surg Onc. in press, Published online at doi: 10.1245/s10434-006-9088-7

77.

Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004;11:274–280.PubMedCrossRef

78.

Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Brit J Surg 2003;90:567–574.PubMedCrossRef

79.

Garcia-Aguilar J, Cromwell JW, Marra C, Lee, S-H, Madoff RD, Rothenberger, DA. Treatment of locally recurrent rectal cancer. Dis Colon & Rectum 2001;44:1743–1748.CrossRef

80.

Lopez-Kostner F, Fazio VW, Vignali A, Rybicki LA, Lavery IC. Locally recurrent rectal cancer predictors and success of salvage surgery. Dis Colon & Rectum 2001;44:173–178.CrossRef

81.

Wiig JN, Larsen SG, Dueland S, Giercksky KE. Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer. J Surg Oncol 2005;92:70–75.PubMedCrossRef

Title: Detection and Management of Extrahepatic Colorectal Cancer in Patients with Resectable Liver Metastases
Authors: Yolanda Y. L. Yang
James W. Fleshman
Steven M. Strasberg
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 7/2007
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-006-0067-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Detection and Management of Extrahepatic Colorectal Cancer in Patients with Resectable Liver Metastases

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2007

A Prospective Evaluation of an Algorithm Incorporating Routine Preoperative Endoscopic Ultrasound-Guided Fine Needle Aspiration in Suspected Pancreatic Cancer

Viability of Endoscopic and Excisional Treatment of Early Rectal Carcinoids

Portal Vein Interposition Using Homologous Iliac Vein Graft during Extensive Resection for Hilar Bile Duct Cancer

Technical Considerations in Laparoscopic Fundoplication

Mild Acute Biliary Pancreatitis vs Cholelithiasis: Are There Differences in the Rate of Choledocholithiasis?

Thyroid Artery Erosion by Esophageal Cancer: Management with Interventional Radiology